Background: Autologous free-fat transplantation is limited by fat absorption and fibrosis due to fat necrosis. In this study, we explored the feasibility of using bone mesenchymal stem cells (BMSCs) transfected by vascular endothelial growth factor (VEGF) 165 gene to improve the survival of transplanted fat tissues in a rat model. Methods: Bone mesenchymal stem cells with (group A) and without (group B) VEGF165 gene transfection were each mixed with free transplanted fat tissue; then, they were injected subcutaneously at sites on the backs of 36 Sprague-Dawley rats. A control group (group C) was established by using low-glucose Dulbecco modified Eagle medium. The transplants from groups A, B, and C were gathered respectively at 30, 90, and 180 days after transplantation.
A utologous free-fat transplantation is an easy and useful way to correct soft tissue defects clinically. The technique was first reported by Neuber in 1893. 1 Although autologous fat transplantation has been refined in the last decades and the outcome in many facilities has improved, 2 it is limited by fat absorption and fibrosis due to fat necrosis. Peer et al 3, 4 reported that the rate of resorption can reach more than 50%. The exact mechanism behind this phenomenon is still in dispute, and most researchers accept the cell survival theory. 5 At the same time, nearly all researchers support the perspective that early blood supply to autologous free-fat transplantation tissue is a key to its survival.
Vascular endothelial growth factor (VEGF) is a potential agent for treating ischemia by inducing angiogenesis. 6 In addition, it may provide endothelial cells protection against ischemic injury. 7 Under special culture conditions, mesenchymal stem cells have the potential to differentiate into osteocytes, chondrocytes, adipocytes, tenocytes, hematopoiesis-supporting stroma, and endothelial cells. 8 In some studies, mesenchymal stem cells have been used to regenerate vessels. 9, 10 Moreover, mesenchymal stem cells demonstrate a low rate of immunity-assisted rejection and divide better without apoptosis than differentiated cells. 11 Compared with other cells, especially adiposederived stem cells (ADSCs), bone mesenchymal stem cells (BMSCs) are thought to give rise to cells that constitute the hematopoietic microenvironment, and the mechanisms of their contribution on vascularization are definite. By contrast, previous studies suggested that ADSCs can support hematopoiesis 12Y14 but that this effect may be transient. 15 Thus, to date, the hematopoiesis-supporting properties of ADSCs have not been fully determined. Bone mesenchymal stem cells transfected by the VEGF gene can show localized enhancement of VEGF levels and lead to successful angiogenesis in animal models of ischemia. 16, 17 For our experiments, we hypothesized that cell transplantation using VEGF-expressing BMSCs could enhance the revascularization of autologous free-fat transplantation tissue. We studied the effect of mesenchymal stem cells transfected by VEGF165 gene on autologous free-fat transplantation using Sprague-Dawley rat models.
MATERIALS AND METHODS

Cell Isolation and Culture
Male Sprague-Dawley rats (Animal Laboratory, The Ninth People's Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China) weighing approximately 100 g were killed by carbon dioxide and then placed into 750 mL/L alcohol for 15 minutes. The humerus, femurs, and tibias of the Sprague-Dawley rats were harvested sterilely under a laminar-flow hood. 18 The bones were opened from both ends, and the marrow was flushed with 10 mL of low-glucose Dulbecco modified Eagle medium (L-DMEM) in a sterile fashion using a blunt-end hypodermic needle with a syringe. All procedures were carried out in accordance with the ''Guide for the Care and Use of Laboratory Animals'' (National Institutes of Health publication no. 85-23, revised 1985) . The cells in L-DMEM were layered over an equal volume of Histopaque-1.077 (Sigma, St. Louis, MO). Centrifugation was performed at 2000 rpm for 30 minutes at room temperature. The mononuclear cell layer was collected from the separated bone marrow sample to begin the culture. Cells were plated in 10-cm plastic cell culture plates at a density of 3 Â 10 5 /mL and maintained with L-DMEM containing 10% fetal bovine serum and 20 Kg/mL of gentamicin (Sigma). The cell cultures in this study were grown at 37-C in a 5% carbon dioxide per 95% air atmosphere. The medium was replaced every 2 days, and nonadherent cells were discarded. Cells were harvested at approximately 90% confluence and then expanded. After a series of passages, the attached marrow cells became homogeneous.
Characterization of Cultured BMSCs
Cultured BMSCs of third passage were analyzed by fluorescence-activated cell sorting (FACScan flow cytometer; Becton Dickinson, Franklin Lakes, NJ). Cells were detached and incubated in phosphate-buffered saline (PBS) containing 2% bovine serum albumin with fluorescein isothiocyanateYconjugated mouse monoclonal antibodies against rat CD31, CD34, CD45, CD90, and CD105 (Becton Dickinson). Quantitative fluorescence-activated cell sorting was performed by flow cytometry at 10,000 cells per sample.
Bone Mesenchymal Stem Cells Gene Transfer In Vitro
Third-passage cell cultures were transfected with plasmid PIRES2-EGFP-hVEGF165 (Cyagen Biosciences, Inc, GuangZhou, China). After dilution of 2 Kg of PIRES2-EGFP-hVEGF165 liposomes with 193 KL of serum-free L-DMEM and 7 KL of FuGENE HD transfection reagent (F. HoffmannYLa Roche, Ltd), the solutions were added to a 35-mm cellular culture dish containing adherent mesenchymal stem cells and 1.8 mL of L-DMEM, which contained 10% fetal bovine serum. Twenty-four hours after transfection, fresh L-DMEM containing 10% fetal bovine serum was added followed by incubation for 48 hours before transplantation.
Human VEGF Expression In Vitro
Bone mesenchymal stem cells were collected from the group transfected with PIRES2-EGFP-hVEGF165, the group transfected with PIRES2-EGFP, and the untransfected group when cell confluence reached 90%. Total RNA was then extracted using Trizol, and their complementary DNA was synthesized by Improm-II TM reverse transcription system kit according to the instructions in the manual (Promega). Primer sequences for VEGF165 messenger RNA designed by PrimerBank software were forward 5 ¶-CAACATCACCATGCA GATTATGC-3 ¶ and reverse 5 ¶-TCGGCTTGTCACATTTTTCTTGT-3 ¶. The length of the product was 137 base pairs (bp). A-Actin of rat was used as primer with length of 587 bp. A reliable, effective, and reproducible polymerase chain reaction (PCR) system for detecting BMSCs was developed. The reaction mixture consisted of 2.0 KL of complementary DNA product, 2.0 KL of 10Â PCR buffer, 0.5 KL of 10 mM deoxyribonucleoside triphosphate, 0.25 KL of 5 U/KL Taq polymerase, and 0.3 KL of each primer in a total volume of 20 KL. The reaction mixture was subjected to 30 cycles of a PCR denaturation step after an initial 5 minutes at 95-C. Each cycle consisted of a 30-second denaturation at 95-C, a 30-second annealing at 55-C, and a 30-second extension at 72-C. The last cycle was followed by a 5-minute elongation step at 72-C. Ten microliters of PCR products were electrophoresed on a 2% agarose gel.
The cell culture medium was changed every day to measure the VEGF concentration over a 24-hour period. The culture medium was respectively collected from VEGF165-transfected mesenchymal stem cells and untransfected cells (n = 6 in each group) at 1, 3, 5, 7, 9, 11, and 14 days after transfection. Vascular endothelial growth factor levels in the medium were quantified using a human VEGF immunoassay kit (R&D Systems, Inc, Minneapolis, MN). Absorbance was measured at 450 nm by means of a microplate reader.
Chloromethyl-1-1 ¶-Dioctadecyl-3,3,3 ¶, 3 ¶-Tetramethylindocarbocyanineperchlorate Staining of Cells
At 3 days after transfection, VEGF165-transfected cells and untransfected cells in suspension were incubated with chloromethyl-1-1 ¶-dioctadecyl-3,3,3 ¶, 3 ¶-tetramethylindocarbocyanineperchlorate (CM-DiI; Molecular Probes, Inc, Eugene, OR) at a concentration of 2.5 Kg/mL in PBS for 5 minutes at 37-C and then for another 15 minutes at 4-C. After 2 washes in PBS, 5 Â 10 6 cells were suspended in 0.3 mL of L-DMEM and suctioned into two 5-mL syringes. Transfected cells were labeled as A, and untransfected cells, as B. Another 5-mL syringe, which suctioned 0.3 mL L-DMEM, was labeled C.
Animal Model and Groups
Thirty-six Sprague-Dawley rats weighing 200 to 250 g served as models for autologous free-fat transplantation. The inguinal fat of each rat was excised and then cut into pieces in sterile plastic cell culture plates. Each fat sample was divided into 3 parts, each weighing 0.300 g on an electronic balance. The prepared A, B, and C syringes were used to suction separated fat, which was then mixed thoroughly. Finally, each rat was injected subcutaneously with 12-gauge needles whose interdiameters were 1.2 mm at 3 sites on the back. Thus, 108 fat transplantations were performed, with each rat receiving all 3 fat mixtures at different sites. The site selected for each of the 3 fat mixtures was made randomly to control for the possibility that the regional subcutaneous blood supply at the sites might differ. At 30 days after transplantation, 12 rats were killed (A, B, and C samples were labeled as A 1 , B 1 , and C 1 , respectively), another 12 rats were killed 90 days after transplantation (A, B, and C samples were labeled as A 2 , B 2 , and C 2 , respectively), and the remaining 12 rats were killed 180 days after transplantation (A, B, and C samples were labeled as A 3 , B 3 , and C 3 , respectively). The transplants were excised and analyzed as described below.
Histopathologic Examination of Transplants
The 3 types of transplants were placed in 4% paraformaldehyde and embedded in paraffin. Tissue sections from the center of the dissected fat biopsy were then stained with hematoxylin-eosin and examined under a light microscope. Intact fat cells were measured as the survival areas by outlining the corresponding areas and analyzed using Image Pro-Plus 5.1 software (Media Cybernetics Company, Silver Spring, MD), using the methods previously described. 19 The ratio of survival areas can be qualified.
Determination of the Origin of the Endothelial Cells in Regenerated Capillaries
The samples were embedded for frozen sectioning and cut into 6-Km-thick slices. Staining for von Willebrand factor (Abcam Ltd, London, England) was used to detect capillary endothelial cells. Briefly, after blocking, the slides were stained overnight at 4-C with rabbit antirat von Willebrand factor antibody and then incubated with fluorescein isothiocyanateYconjugated antirabbit IgG antibody for 30 minutes. After washing with PBS twice, the green fluorescence of fluorescein isothiocyanate was detected. After photographs were taken, the slide was placed under a green fluorescent beam, which allowed the detection of the CM-DiIYlabeled exogenous BMSCs. The green and red fluorescent images were merged by Lumina Vision V220 imaging software (Olympus, Tokyo, Japan). The overlapping red and green fluorescence appeared yellow, which indicated that the endothelial cells in the regenerated capillaries were from the transplanted CM-DiIYpositive BMSCs. Revascularization was assessed by counting the capillaries in 20 fields of each immunofluorescence slide (original magnification, Â40). The counting was performed by 2 blinded reviewers.
Statistical Analysis
All results were expressed as mean (SEM). Statistical significance was evaluated by analysis of variance using SPSS software version 15.0 for Windows (SPSS, Chicago, IL). P G 0.05 was considered to denote statistical significance.
RESULTS
Characterization of BMSCs
The phenotypic characterization of BMSCs was analyzed by fluorescence-activated cell sorting. The results showed that these cells did not express CD31, CD34, or CD45. However, almost all cells expressed CD90 and CD105 (Fig. 1 ). CD31 and CD34 are surface markers of hematopoietic progenitors, CD45 is a lymphocytic surface marker, and CD90 and CD105 are major surface markers of mesenchymal cells. These findings indicate that the cells we used originate from bone marrow stroma.
Transgene VEGF165 Expression In Vitro
Under the fluorescence microscope, we observed that most of the cells were transfected (Fig. 2) . Results of reverse transcriptaseY PCR showed a new 137-bp band in the PIRES2-EGFP-hVEGF165Y transfected group. There was no band in the other 2 groups (Fig. 3 1, 3, 5, 7, 9, 11 , and 14 days after transfection, respectively. The level of VEGF of the transfected BMSCs was significantly increased and reached a peak on day 7; almost no VEGF was detectable in the culture medium of untransfected cells (Fig. 4 ).
Assessment of Fat Tissue Survival
The fat tissues were mixed with CM-DiIYlabeled VEGF165transfected BMSCs (A 1 , A 2 , A 3 ), CM-DiIYlabeled cells (B 1 , B 2 , B 3 ), and L-DMEM (C 1 , C 2 , C 3 ). Each rat was injected with all 3 fat mixtures, each of the 3 designated injection sites randomly received 1 of these 3 fat mixtures. None of the animals died during the experiment. The weight of the transplants was used to calculate the survival ratio using the ration of survival weight to initial weight (0.3 g). At 30 days after transplantation, the mean (SD) survival ratios for A 1 , B 1 , and C 1 were 86.2% (4.2%), 70.7% (3.5%), and 54.5% (4.0%), respectively. The differences among the groups were all statistically significant (P G 0.05). At 90 days after transplantation, the mean (SD) survival ratios for A 2 , B 2 , and C 2 were 82.3% (7.8%), 60.5% (7.8%), and 32.4% (5.9%), respectively. The differences among the groups were all statistically significant (P G 0.05). At 180 days after transplantation, the mean (SD) survival ratios for A 3 , B 3 , and C 3 were 82.4% (4.8%), 59.2% (6.2%), and 29.6% (3.7%), respectively. The differences among the groups were all statistically significant (P G 0.05). The differences among survival ratios of A 1 , A 2 and A 3 were not statistically significant (P 9 0.05). However, survival ratio of B 1 was higher than B 2 and B 3 (P G 0.05). The survival ratio of B 2 groups was not statistically higher than B 3 (P 9 0.05). The outcomes of the C group were similar to those of the B group (Figs. 5, 6). groups A and B consisted predominantly of surviving mature adipose tissue and had significantly lower levels of fat necrosis and fibrosis (P G 0.05); both transplants also exhibited the histologic structure of normal fat tissue. The differences among A 1 , A 2 and A 3 were not significant (P 9 0.05). However, the necrosis of B 1 was less than that of B 2 and B 3 (P G 0.05). The necrosis of B 2 was not statistically less than that of B 3 (P 9 0.05). The outcomes of the C groups were similar to those of the B groups (Figs. 7, 8 ).
Differentiation of BMSCs in Survival Transplants
The survival of transplanted BMSCs was demonstrated by the presence of CM-DiIYlabeled cells. BMSCs were also detected in vascular structures, in which they expressed von Willebrand factor, suggesting the differentiation of BMSCs into endothelium and their incorporation into the vessel wall in group A. No CM-DiIYlabeled BMSCs were detected that had been incorporated into the vessel wall in group B. There were no BMSCs detected in group C ( Fig. 9 ).
Capillary Density
Evaluation of 20 fields per section taken from the center of the surviving fat tissue allowed us to determine capillary density, which is an index of revascularization. At 30 days after transplantation, the mean (SD) capillary densities for groups A 1 , B 1 and C 1 were 26.4 (3.02), 13.90 (3.90), and 5.60 (2.26), respectively. The differences among the groups were all statistically significant (P G 0.05). At 90 days after transplantation, the mean (SD) capillary densities for groups A 2 , B 2 , and C 2 were 25.95 (2.96), 14.45 (2.81), and 4.25 (1.90), respectively. The differences among the groups were all statistically significant (P G 0.05). At 180 days after transplantation, the mean (SD) capillary densities for groups A 3 , B 3 , and C 3 were 25.00 (3.00), 14.05 (2.66), and 5.35 (1.95), respectively. The differences among the groups were all statistically significant (P G 0.05). The differences among the A 1 , A 2 , and A 3 were not statistically significant (P 9 0.05). The outcomes of groups B and C were similar to those of group A (Fig. 10 ).
DISCUSSION
Filling soft tissue and contour defects, especially on the face, always puzzles plastic surgeons. Because the material used in autologous free-fat transplantation is relatively cheap, easy to harvest, available in large quantities, and autogenic, more and more plastic surgeons prefer to use it. However, the main disadvantage of this technique is the high absorption rate of the transplanted fat, which can reach up to 70% of its volume, hence a need for overcorrection and repeated operations. 20Y22 Therefore, further improvements to autologous free-fat transplantation to increase its efficiency are required.
Histologic examinations of autologous free-fat transplants showed slight necrosis of the adipocytes 48 hours after grafting, with only partial revascularization. On the fourth day, revascularization of the graft occurs by neoangiogenesis from the host bed vascular system. However, the process of revascularization is largely limited, to the periphery, leaving central cells with marginal access to a vascular supply. 23 Within 8 days of fat grafting, they lose their fat vacuole. Therefore, an early blood supply to transplanted fat tissues is critical for the survival of adipocytes, which are sensitive to ischemia. Some authors have examined the expression of VEGF during angiogenesis in the grafted fat tissue by immunohistochemical staining. Angiogenic factors, including VEGF, were found to start revascularization of the graft at approximately day 7 after grafting. Thus, the clinical application of angiogenic factors to fat grafts was suggested to contribute to the survival of the grafts. 24 Vascular endothelial growth factor can induce angiogenesis and endothelial cell proliferation and stimulates vascular permeability. 6 The different isoforms of VEGF are classified on the basis of their affinity to heparin; VEGF is the most physiologically active. 25 Vascular endothelial growth factor has been shown to enhance revascularization of ischemic tissues when used topically and injected intravenously. 26 Because the half-life of VEGF is short and its price is very high, 6 gene therapy using the VEGF gene has been proposed for free-fat transplantation and confirmed to be useful. 27 Compared with other cells, BMSCs can be multiplied quickly in vitro. 8 Moreover, BMSCs are relatively undifferentiated precursor cells with the ability to develop into a wide variety of tissue types. Some studies have shown that BMSCs can differentiate into endothelial cells and form tubelike structures in vitro when cultured in the presence of VEGF and that BMSCs can also differentiate into vasculature-forming cells when genetically transfected to express VEGF. 28 Therefore, BMSCs can serve as ideal cells for gene therapy. Lu and Li 27 used VEGF165-transfected ADSCs to improve the survival of grafted fat. The ADSCs prepared from human liposuction for different studies differ in purity and molecular phenotype, with many studies using cell preparations that are likely to contain heterogeneous populations of cells, making it uncertain whether ADSCs themselves are responsible for effects observed. Hence, although 1 clinical ap-plication already looks convincing, the full clinical potential of ADSCs awaits much deeper investigation of their fundamental biology. 29 In addition, limited to current technology on extracting ADSCs, we usually need to liposuction hundreds milliliters of fat to gain sufficient quantities of ADSCs. At the same time, because abundant fat tissues are requisite to fill soft tissue and contour defects, this may seem very difficult for patients who are thin (especially oriental). Under this condition, BMSCs may have evident advantage over ADSCs.
Based on the above findings, we used transplantation of BMSCs transfected to overexpress VEGF and mixed them with autologous fat tissue to improve angiogenesis and survival of the grafted fat in a rat model. There are 2 advantages with this approach. First, VEGF165-transfected cells can secrete VEGF, and second, the cells also participate in tissue regeneration. In our experiments, 30 days after fat transplantation, the VEGF165-transfected group had higher blood density than the other 2 groups. In addition, the survival ratio of the VEGF165-transduced group did not decline at 90 days or 180 days after transplantation in comparison with 30 days. In contrast, the other 2 groups did not regenerate enough vessels 30 days FIGURE 7. Panels a1, a2, and a3 respectively correspond to groups A, B, and C at 30 days after transplantation. Panels b1, b2, and b3 respectively correspond to groups A, B, and C at 90 days after transplantation. Panels c1, c2, and c3 respectively correspond to groups A, B, and C at 180 days after transplantation (original magnification, Â40). Size bar: 100 Km. after transplantation. Therefore, they both atrophied to varying extents 30 days after transplantation and had stabilized 90 days after transplantation. Thus, early and abundant neovascularization seems to be a key to the survival of free-fat transplants, which in turn leads to good transplant outcomes.
Cell therapy and gene therapy have been proven to be effective for promoting neovascularization in various animal models. 30 Moreover, some studies have demonstrated the superiority of combined therapy compared with monotherapy. 27, 31 In our study, the survival ratio of the VEGF165-transfected group was higher than that of the untransfected group, which supports the viewpoint.
We found that mixing the fat tissues with BMSCs before autologous free-fat transplantation could significantly increase their capillary density and survival ratio. Although it remains unclear how the stem cells enhanced the survival of the fat transplants, our data support the following possibilities. First, the VEGF165-transfected group could secrete much more VEGF. This showed that BMSCs could be effectively transfected by the VEGF165 gene, and they can continually secrete VEGF afterward. The concentration of VEGF reached a peak 7 days after transplantation, which then promoted early revascularization and enhanced adipocytes' survival. Because the 3 groups evidently differed in capillary density and fat viability, we concluded that VEGF can improve the revascularization and viability of autologous transplanted fat tissue. Second, we found that some of the CM-DiIYpositive endothelial cells in the VEGF165transfected group were also von Willebrand factor positive, which indicated that these cells had differentiated from labeled BMSCs. The differentiation of BMSCs into vascular endothelial cells may promote the revascularization that enhances the survival of the transplants. Third, we detected CM-DiIYlabeled stem cells in the surviving fat tissue, which indicated that some of the adipocytes in the tissue were derived from the exogenous BMSCs, thus the differentiation of some stem cells into mature adipocytes that may partly compensate for some loss of transplanted tissue. This could explain why the survival ratio of the untransfected group was higher than that of the control group. Lastly, the survival ratio and capillary densities of the transfected group were higher than that of the untransfected group. These indicated that both improved revascularization and the viability of the autologous transplanted fat tissue require the cooperative and continuous action of BMSCs with VEGF.
CONCLUSIONS
We observed that untransfected BMSCs can also improve the survival of transplanted fat tissue, and this may be useful in clinical fat transplantation. However, the combined strategy of cell transplantation with gene therapy could achieve a higher survival ratio of autologous free-fat transplantation. These results showed that a sustained high concentration of VEGF and the role of BMSCs in transplanted fat tissues are both very important for their survival. With the development of transgenic technology, our method is expected to be applied clinically. It can be an alternative method, especially in thin patients. Because this approach has such merits as less trauma, an easy operation, and good prospects for its application, we believe that it can provide a new way to improve the survival rate of autologous free-fat transplantation. Honestly, this research was based on an animal model and assessed transplantation of a small amount of fat. Further research is needed to make sure that this method can be used for larger animals, including humans.
